Breaking News Instant updates and real-time market news.

AAPL

Apple

$168.38

-4.42 (-2.56%)

, FB

Facebook

$157.20

-2.14 (-1.34%)

07:51
04/09/18
04/09
07:51
04/09/18
07:51

Apple co-founder Steve Wozniak leaving Facebook, USA Today reports

Apple (AAPL) co-founder Steve Wozniak tells USA Today that he is leaving Facebook (FB), saying ""Users provide every detail of their life to Facebook and... Facebook makes a lot of advertising money off this... The profits are all based on the user's info, but the users get none of the profits back." Commenting on Apple, Wozniak said "Apple makes its money off of good products, not off of you," adding that "As they say, with Facebook, you are the product." Reference Link

AAPL

Apple

$168.38

-4.42 (-2.56%)

FB

Facebook

$157.20

-2.14 (-1.34%)

  • 09

    Apr

  • 10

    Apr

  • 10

    Apr

  • 11

    Apr

  • 11

    Apr

  • 17

    Apr

  • 25

    Apr

AAPL Apple
$168.38

-4.42 (-2.56%)

04/05/18
SBSH
04/05/18
NO CHANGE
Target $200
SBSH
Buy
Citi sees $100B opportunity in Apple's capital returns strategy
Citi analyst Jim Suva reiterates a Buy rating on Apple shares with a $200 price target. The analyst expects "volatility ahead" for the stock as consensus estimates for the March and June quarters move lower to reflect more tempered demand for the iPhone X. Looking ahead, however, Suva expects investor focus to be on the impact from Apple's capital returns strategy. He estimates this could be a $100B increase. Investors will also soon focus on Apple's second half of 2018 product lineup and continued strength in its Services segment, Suva tells investors in a research note.
04/04/18
BERN
04/04/18
NO CHANGE
BERN
Market Perform
Narrowing gap between TSMC, Intel makes Apple's aspiration possible, says Bernstein
Bernstein analyst Mark Li believes that given Apple's (AAPL) experience in processor design, replacing Intel (INTC) processor with its own is possible. Further, the analyst says that the narrowing gap in process technology between TSMC (TSM) and Intel also makes Apple's aspiration possible, while Apple's vertical integration with OS and applications also puts it in a better position to challenge Intel. Li sees a downside to TSMC's 2019 revenue because of Bitcoin, but says it remains a "solid" company with balanced risk and reward. The analyst reiterates a Market-Perform rating on TSMC shares.
04/03/18
MSCO
04/03/18
NO CHANGE
Target $43
MSCO
Equal Weight
Intel has limited risk from 'recurring' Apple concerns, says Morgan Stanley
After Bloomberg reported yesterday that Apple (AAPL) is evaluating using its own processors in Mac computers, Morgan Stanley analyst Joseph Moore noted that this has been a recurring concern in recent years for Intel (INTC). Ensuring backwards compatibility with prior Macs would require emulation, which could be problematic for Apple given that ARM processors have lower performance for most common PC applications, said Moore. The analyst, who doesn't see Intel's roughly 4% exposure to Macs being fully at risk, maintains his Equal Weight rating on Intel shares.
04/03/18
RBCM
04/03/18
NO CHANGE
Target $46
RBCM
Sector Perform
Apple's chip insourcing to have modest impact on Intel, says RBC Capital
RBC Capital analyst Amit Daryanani writes that yesterday's Bloomberg report about Apple's (AAPL) plans to replace Intel (INTC) x86 processor solutions in its Mac product line is likely to have a "modest" impact of annual 20c-25c EPS and $3B-$4B on Intel over longer term. Daryanani believes that the initiative is still at an early stage and his assumption accounts for a total loss of Apple's processor allocation, though he also warns that Apple's insourcing could create a business impact on the broader supply chain. The analyst keeps his Sector Perform rating and $46 price target on Intel, maintaining a neutral stance on the possibility of heightened competition from AMD's (AMD) Epyc processor.
FB Facebook
$157.20

-2.14 (-1.34%)

04/05/18
WELS
04/05/18
NO CHANGE
Target $230
WELS
Outperform
Facebook expected to 'weather the storm,' says Wells Fargo
Wells Fargo analyst Ken Sena says his advertising and agency contacts continue to point to the fact that marketers with direct and purchased access to third party data will still be able to apply it to Facebook targeting. Moreover, combined with the fact that Facebook's first party data and advertiser's customer data will continue to be applicable to Facebook targeting, the analyst expects no material negative impact on advertiser spending. Sena reiterates an Outperform rating and $230 price target on the shares.
04/04/18
SPHN
04/04/18
NO CHANGE
Target $32
SPHN
Overweight
Acxiom overreaction to Facebook news a buying opportunity, says Stephens
Stephens analyst Brett Huff noted that Acxiom (ACXM) CEO Scott Howe published a blog post stating that he has seen "some signs" that Facebook (FB) is reconsidering its new policy on data imports in light of advertiser concerns. Huff, who thinks the blog post is a potential indication of the level of concern advertisers are having about Facebook's recent move, remains a buyer of Acxiom shares as he views the recent negative stock reaction to Facebook's news as overdone. He maintains his $32 price target and Overweight rating on Acxiom shares.
04/04/18
SBSH
04/04/18
NO CHANGE
SBSH
Buy
Facebook pullback brings long-term opportunity, says Citi
Citi analyst Mark May believes the recent selloff in shares of Facebook brings an opportunity for long-term minded investors. The analyst, however, believes the company's current situation is "difficult to quantify" and he expects near-term volatility to persist. May maintains a Buy rating on Facebook.
04/04/18
MSCO
04/04/18
NO CHANGE
Target $200
MSCO
Overweight
Morgan Stanley still bullish on Facebook, but trims target to $200
After having spoken with eight agencies/advertisers about Facebook following the company's recent data and privacy issues and its announcement that it will end partnerships with third party data providers, Morgan Stanley analyst Brian Nowak said he did not sense any material reduction in ad spend. He actually thinks the elimination of third parties is smart strategically over the long-term, as he sees it highlighting Facebook's leading reach and first party data advantage. While he noted his agency conversations were positive, Nowak also acknowledged his sample "is far from statistically significant." Feeling it appropriate to be more conservative in the near-term, he lowered his 2018 and 2019 ad revenue estimates for Facebook by 2% and 3%, respectively, and cut his price target to $200 from $230, also citing increased expectations for investment in data safety. Nowak, who said he is still bullish on Facebook, keeps an Overweight rating on the name.

TODAY'S FREE FLY STORIES

01:50
11/15/18
11/15
01:50
11/15/18
01:50
General news
Asian Market Wrap: »

Asian Market Wrap:…

APTX

Aptinyx

$24.75

-0.76 (-2.98%)

21:40
11/14/18
11/14
21:40
11/14/18
21:40
Initiation
Aptinyx initiated at Cantor Fitzgerald »

Aptinyx initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OVID

Ovid Therapeutics

$4.75

-0.42 (-8.12%)

21:39
11/14/18
11/14
21:39
11/14/18
21:39
Initiation
Ovid Therapeutics initiated at Cantor Fitzgerald »

Ovid Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AXSM

Axsome Therapeutics

$2.82

-0.07 (-2.42%)

21:38
11/14/18
11/14
21:38
11/14/18
21:38
Initiation
Axsome Therapeutics initiated at Cantor Fitzgerald »

Axsome Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNLI

Denali Therapeutics

$17.53

0.24 (1.39%)

21:37
11/14/18
11/14
21:37
11/14/18
21:37
Initiation
Denali Therapeutics initiated at Cantor Fitzgerald »

Denali Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIC

Otonomy

$2.34

-0.07 (-2.90%)

21:35
11/14/18
11/14
21:35
11/14/18
21:35
Initiation
Otonomy initiated at Cantor Fitzgerald »

Otonomy initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

AAPL

Apple

$186.81

-5.42 (-2.82%)

20:46
11/14/18
11/14
20:46
11/14/18
20:46
Hot Stocks
Apple supplier AMS AG discontinues FY18 targets »

Ams updates its fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

WEI

Weidai

$0.00

(0.00%)

20:33
11/14/18
11/14
20:33
11/14/18
20:33
Syndicate
Weidai 4.5M share IPO priced at $10.00 »

The deal was priced at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

CPB

Campbell Soup

$39.16

-0.1 (-0.25%)

20:31
11/14/18
11/14
20:31
11/14/18
20:31
Hot Stocks
Campbell Soup responds to ISS regarding board elections »

Campbell Soup issued the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CRM

Salesforce

$129.25

-2.93 (-2.22%)

20:25
11/14/18
11/14
20:25
11/14/18
20:25
Periodicals
Breaking Periodicals news story on Salesforce »

Salesforce to accommodate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

WMT

Walmart

$101.58

-1.37 (-1.33%)

, JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

20:25
11/14/18
11/14
20:25
11/14/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$101.58

-1.37 (-1.33%)

JCP

J.C. Penney

$1.23

-0.05 (-3.91%)

BERY

Berry Global

$45.91

-0.49 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 15

    Nov

  • 15

    Nov

BHVN

Biohaven Pharmaceutical

$33.70

-3.18 (-8.62%)

19:53
11/14/18
11/14
19:53
11/14/18
19:53
Recommendations
Biohaven Pharmaceutical analyst commentary at Piper Jaffray »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$143.69

-15.62 (-9.80%)

19:51
11/14/18
11/14
19:51
11/14/18
19:51
Initiation
Loxo Oncology initiated at Raymond James »

Loxo Oncology initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 15

    Nov

  • 26

    Nov

  • 27

    Nov

OCUL

Ocular Therapeutix

$5.06

-0.25 (-4.71%)

19:50
11/14/18
11/14
19:50
11/14/18
19:50
Initiation
Ocular Therapeutix initiated at Raymond James »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Dec

VYGR

Voyager Therapeutics

$11.25

-0.54 (-4.58%)

19:49
11/14/18
11/14
19:49
11/14/18
19:49
Upgrade
Voyager Therapeutics rating change at Raymond James »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GLPG

Galapagos NV

$103.79

1.03 (1.00%)

19:48
11/14/18
11/14
19:48
11/14/18
19:48
Initiation
Galapagos NV initiated at Raymond James »

Galapagos NV initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COPY

CopyTele

$0.00

(0.00%)

19:47
11/14/18
11/14
19:47
11/14/18
19:47
Upgrade
CopyTele rating change at BMO Capital »

CopyTele upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICI

VICI Properties

$21.43

-0.04 (-0.19%)

19:40
11/14/18
11/14
19:40
11/14/18
19:40
Syndicate
VICI Properties 30M share Secondary priced at $21.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

WHD

Cactus

$32.37

-0.7 (-2.12%)

19:37
11/14/18
11/14
19:37
11/14/18
19:37
Hot Stocks
Cactus names Stephen Tadlock new CFO »

Cactus announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVLT

Revolution Lighting

$1.42

(0.00%)

19:32
11/14/18
11/14
19:32
11/14/18
19:32
Hot Stocks
Revolution Lighting receives revised $1.50 per share proposal from RVL LLC »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$8.34

-0.265 (-3.08%)

19:20
11/14/18
11/14
19:20
11/14/18
19:20
Periodicals
General Electric withdraws from Nigeria rail concession, Reuters says »

GE has withdrawn from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCSF

Bain Capital Specialty Finance

$0.00

(0.00%)

19:11
11/14/18
11/14
19:11
11/14/18
19:11
Syndicate
Bain Capital Specialty Finance 7.5M share IPO price $20.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

TSLA

Tesla

$344.07

5.36 (1.58%)

19:07
11/14/18
11/14
19:07
11/14/18
19:07
Periodicals
Tesla Model 3 owners experience issues in cold weather, Electrek says »

Tesla Model 3 will face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 19

    Nov

  • 19

    Nov

  • 13

    Dec

NGHC

National General

$24.75

-3.05 (-10.97%)

19:05
11/14/18
11/14
19:05
11/14/18
19:05
Syndicate
National General 5M share Secondary priced at $24.00 »

JPMorgan, Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 15

    Nov

WMT

Walmart

$101.58

-1.37 (-1.33%)

19:01
11/14/18
11/14
19:01
11/14/18
19:01
Periodicals
Walmart's Cornershop to expand into Canada next year, Reuters says »

Cornershop, a Latin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.